InTextoResearch vous informe sur les dernières parutions d'articles
de
revue sur le cancer de la prostate (31 mai 2008):

Role of hormonal and other factors in human prostate cancer.
Wigle DT, Turner MC, Gomes J, Parent ME.
J Toxicol Environ Health B Crit Rev. 2008 Mar;11(3-4):242-59.

Calcitriol as a chemopreventive and therapeutic agent in prostate
cancer: role of anti-inflammatory activity.
Krishnan AV, Moreno J, Nonn L, Swami S, Peehl DM, Feldman D.
J Bone Miner Res. 2007 Dec;22 Suppl 2:V74-80.

Prostate-specific antigen and prostate cancer: prediction, detection
and monitoring.
Lilja H, Ulmert D, Vickers AJ.
Nat Rev Cancer. 2008 Apr;8(4):268-78.

Natural and synthetic agents targeting inflammation and angiogenesis
for chemoprevention of prostate cancer.
Araldi EM, Dell'aica I, Sogno I, Lorusso G, Garbisa S, Albini A.
Curr Cancer Drug Targets. 2008 Mar;8(2):146-55.

The emergence of DNA methylation as a key modulator of aberrant cell
death in prostate cancer.
Murphy TM, Perry AS, Lawler M.
Endocr Relat Cancer. 2008 Mar;15(1):11-25.

Chemotherapy in hormone-refractory prostate cancer.
de Wit R.
BJU Int. 2008 Mar;101 Suppl 2:11-5.

Cell signaling modifiers in prostate cancer.
Chen FL, Armstrong AJ, George DJ.
Cancer J. 2008 Jan-Feb;14(1):40-5.

The role of angiogenesis inhibitors in prostate cancer.
Aragon-Ching JB, Dahut WL.
Cancer J. 2008 Jan-Feb;14(1):20-5.

Promising novel cytotoxic agents and combinations in metastatic
prostate cancer.
Bradley DA, Hussain M.
Cancer J. 2008 Jan-Feb;14(1):15-9.

Zoledronic acid: a pharmacoeconomic review of its use in the
management of bone metastases.
McKeage K, Plosker GL.
Pharmacoeconomics. 2008;26(3):251-68.

The rationale for inhibiting 5alpha-reductase isoenzymes in the
prevention and treatment of prostate cancer.
Tindall DJ, Rittmaster RS.
J Urol. 2008 Apr;179(4):1235-42.

Indium-111 capromab pendetide in the management of recurrent prostate
cancer.
Manyak MJ.
Expert Rev Anticancer Ther. 2008 Feb;8(2):175-81.

Predictive models and prostate cancer.
Karakiewicz PI, Hutterer GC.
Nat Clin Pract Urol. 2008 Feb;5(2):82-92.

Ellagic acid, pomegranate and prostate cancer -- a mini review.
Bell C, Hawthorne S.
J Pharm Pharmacol. 2008 Feb;60(2):139-44.

Docetaxel treatment in the elderly patient with hormone refractory
prostate cancer.
Sinibaldi VJ.
Clin Interv Aging. 2007;2(4):555-60.

The androgen receptor as putative therapeutic target in hormone-
refractory prostate cancer.
Kageyama Y, Hyochi N, Kihara K, Sugiyama H.
Recent Patents Anticancer Drug Discov. 2007 Nov;2(3):203-11.

Prostate-specific antigen screening: friend or foe?
Linn MM, Ball RA, Maradiegue A.
Urol Nurs. 2007 Dec;27(6):481-9

Profiling influences of senescent and aged fibroblasts on prostate
carcinogenesis.
Dean JP, Nelson PS.
Br J Cancer. 2008 Jan 29;98(2):245-9

Androgen-deprivation-therapy-induced fractures in men with
nonmetastatic prostate cancer: what do we really know?
Higano CS.
Nat Clin Pract Urol. 2008 Jan;5(1):24-34.

Salvage surgery for locally recurrent prostate cancer after radiation
therapy: tricks of the trade.
Leibovici D, Spiess PE, Heller L, Rodriguez-Bigas M, Chang G, Pisters
LL.
Urol Oncol. 2008 Jan-Feb;26(1):9-16.

(contact pour InTextoResearch: Marc Lacroix, Baelen, Wallonie,
Belgique - scimed...@mail.com)